Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Stefan Faderl(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Miloslav Beran(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Francis J. Giles(Northwestern University), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Charles Koller(The University of Texas MD Anderson Cancer Center), William G. Wierda(The University of Texas MD Anderson Cancer Center), Barbara Pro(The University of Texas MD Anderson Cancer Center), Tran Ngoc(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)
Blood
April 21, 2003
10.1182/blood-2002-07-1952
Cited by 254

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k